Skip to main content
Explore URMC
menu

Sarcoma: Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Research Question:
How safe and effective is treatment with MLN0128 when used to treat sarcoma?

Basic Study Information

Purpose:
You will receive the MLN0128 for as long as the drug is preventing your cancer from growing and the side effects are reasonable. After you finish taking MLN0128, your doctor will continue to watch you for side effects and follow your condition for at least 30 days. Your doctor will continue to watch you for up to 2 years after you begin treatment.

Location: University of Rochester Medical Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02601209?term=A091304&rank=1
Study Reference #: CSAR-16008

Lead Researcher (Principal Investigator)

Lead Researcher: Deepak Sahasrabudhe, MD

Study Contact Information

Study Coordinator: Park Bogan
Phone: (585) 275-3351
Email: Park_Bogan@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Sarcoma

Return to Search